21.01.2020 14:24:11

Seattle Genetics Achieves Milestone On EU Approval Of Roche's Polivy

(RTTNews) - Seattle Genetics Inc. (SGEN) said that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy.

Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' technology. It was developed and is commercialized by Roche/Genentech.

Polivy was approved in combination with bendamustine plus MabThera for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant.

Polivy was granted PRIME designation by the European Medicines Agency for the treatment of people with R/R DLBCL in 2017.

Nachrichten zu Seattle Genetics Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Seattle Genetics Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!